Revelation Biosciences Grants Restricted Stock to CEO and CFO

What Happened Revelation Biosciences, Inc. announced on Form 8-K (filed Aug 19, 2026) that its Compensation Committee approved restricted stock awards effective August 17, 2026 for CEO James Rolke (208,076 shares) and CFO Chester S. Zygmont, III (208,073 shares). Each award vests in four equal 25% tranches based on achieving market-capitalization milestones or on time-based anniversaries, and will fully vest on a qualifying Change in Control or upon certain termination events (death, termination without Cause by the company, or resignation for Good Reason).

Key Details

• Grant date/effective date: August 17, 2026; 8-K filed August 19, 2026.
• Shares granted: 208,076 to CEO James Rolke; 208,073 to CFO Chester Zygmont — 416,149 shares combined.
• Vesting triggers: four 25% tranches tied to either market-cap milestones reached for 20 consecutive trading days or fixed anniversaries:
  • 25% at $30 million market cap or 2nd anniversary;
  • 25% at $60 million market cap or 2nd anniversary;
  • 25% at $90 million market cap or 4th anniversary;
  • 25% at $120 million market cap or 4th anniversary.
• Market cap is calculated using the closing sale price on the principal exchange multiplied by outstanding shares as of that trading day. Awards become fully vested on a Change in Control (subject to plan terms) and upon death, termination without Cause, or resignation for Good Reason.

Why It Matters These awards align the CEO’s and CFO’s compensation with increases in the company’s market capitalization, giving executives incentives tied to stock-price performance. For investors, the grant represents potential dilution of up to 416,149 shares if and when those awards vest and are issued; timing depends on market-cap milestones or the anniversary vesting dates, and certain corporate events or terminations can accelerate vesting. The awards and the form of the restricted stock agreement are governed by the company’s 2021 Equity Incentive Plan (filed previously) and the form agreement included with this 8-K.